By demonstrating that the angiotensin II (Ang II) receptor antagonist (Sar',Val5, Ala8)-Ang II blocks ovulation in immature rats treated with pregnant mares' serum gonadotropin (PMSG) and human chorionic gonadotropin (hCG), Pellicer et al. (1) propose "a direct, obligate role for Ang II in ovulation." This conclusion presents an interesting conceptual problem regarding the site of action of Ang II within the ovary. Since our studies on the adult cycling female rat have shown the lack of Ang II receptors on preovulatory follicles (2), we felt that either (i) the PMSG + hCG-treated immature rat model of ovulation differed significantly from that for the adult female rat with respect to the occurrence ofAng II receptors in the preovulatory follicle; (ii) the Ang II receptor antagonist (Sar',Val5,Ala8)-Ang II displayed nonspecific effects on the process of ovulation; or (iii) the effects of endogenous Ang II on the preovulatory follicle were indirect.
To examine whether Ang II receptors are present in preovulatory follicles in the PMSG-treated or in the PMSG + hCGtreated immature rat ovary, we removed ovaries for receptor autoradiography from three rats each, 48 hours after PMSG treatment and 3 hours after hCG treatment in rats primed 51 hours earlier with PMSG. We chose these two time points such that they were within the period of maximum sensitivity for ovulation inhibition by (Sari, Val5,Ala8)-Ang II as reported by Pellicer et al. (1) . Preovulatory follicular granulosa cells characteristically express luteinizing hormone (LH) receptors (3). In both sets of ovaries, we observed LH receptors, identified by specific 125I-labeled hCG binding (4) , on the granulosa cell layer of certain large follicles (.400-im diameter); these were therefore characterized as preovulatory follicles. LH receptors were also present on the theca cell layers of most follicles. In ovarian sections adjacent to those used for the localization of LH receptors, we localized Ang II receptors using the radiolabeled Ang II receptor antagonist '251-labeled (Sar',Ile8)-Ang II (2) . We examined more than 600 follicles. We found that, in ovaries from both the PMSG-primed and the PMSG + hCG-treated rats, follicles con Antagonists were administered intraperitoneally 1 hour before the hCG treatment. In contrast to the -50% reduction in the number of ova reported by Pellicer et al.
(1), we observed no significant differences (P > 0.05; analysis ofvariance) between the number of oviductal ova of the vehicle injected control rats [22.7 ± 2.0 ova (mean ± SEM), n = 23] and the oviductal ova of the (Sari,Ile8)-Ang II-treated rats [18.6 ± 1.9 ova (mean ± SEM), n = 10] or the (Sar',Val5,Ala8)-Ang II-treated rats [20.5 ± 2.5 ova (mean ± SEM), n = 14]. Since we used the same strain (Sprague-Dawley) and age of rat (25 days old at the time of PMSG treatment), the same dosage (100 ,ul of a 1 mM solution of antagonist), route (intraperitoneal), and time (1 hour before hCG injection) of administration of Ang II receptor antagonist and the same dose and intervals of gonadotropin treatment in this study as those reported by Pellicer et al. (1), our inability to reproduce their experiment cannot be accounted for by these factors.
Although we followed the experimental protocol reported by Pellicer et al. (1), it is possible that in the rat ovary the "window of 
We had also performed a similar group of experiments using 200 ,ul of 1 mM saralasin, but since the results were the same and we had not done full time curves, these experiments were not included in the report. In all cases we found a diminished number of tubal oocytes when saralasin was administered around the time of injection of human chorionic gonadotropin (hCG) in immature rats primed with pregnant mare serum gonadotropin (PMSG). Only in those rats given saralasin 5 hours after hCG was the decreased number of tubal oocytes not statistically significant. (Table 1) .
Although we have been able to reproduce our previous findings, we cannot explain the difference between our previous experience, when saralasin regularly diminished the number of hCG-induced tubal oocytes, and our present findings. We believe that some of the difficulty stems from the difference in maturity of the test animals, and we are exploring this variable. We are also assessing the precision of responses with each of the reagents, especially the biologically derived hormone preparations (PMSG and hCG). At present we are investigating different preparations of hCG. Our preliminary results indicate that the variability of this biologically derived hormone may be responsible for the discrepancies present in this work. Using another preparation of hCG, we have observed a statistically significant difference (P < 0.05) between the With regard to the general issue of angiotensin's role in ovulation, it is of interest that another laboratory has confirmed the action of saralasin in blocking PMS-induced ovulation, using an in vitro perfusion system. Peterson et al. (2) have employed perfusion with luteinizing hormone and isobutyl methyl xanthine of ovaries from 27-day-old female rats which had 48 hours previously received 30 IU of PMSG. Under these conditions the addition of 1 nM of saralasin [(Sar1,Val5,Ala8)-AII], to the perfusion fluid inhibited ovulations by approximately two-thirds. In further studies they completely abolished the saralasin effect by adding angiotensin II to the perfusion medium (3). Their success with luteinizing hormone again focuses interest on the possibility that hCG is the source of the irregularity in the in vivo studies. These independently performed in vitro studies support our original contention that the role of luteinizing hormone in ovulation may require the action of angiotensin.
